These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17344864)

  • 1. Messing with home brews.
    Nat Biotechnol; 2007 Mar; 25(3):262. PubMed ID: 17344864
    [No Abstract]   [Full Text] [Related]  

  • 2. How will the FDA impact the laboratory developed test?
    Davis J; Wentz J
    Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
    [No Abstract]   [Full Text] [Related]  

  • 3. Home health tests are 'genetic horoscopes'.
    Russo G
    Nature; 2006 Aug; 442(7102):497. PubMed ID: 16885953
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA resists regulatory role in gene tests.
    Wadman M
    Nature; 1996 Nov; 384(6605):101. PubMed ID: 8906776
    [No Abstract]   [Full Text] [Related]  

  • 6. Personal genetic tests facing scrutiny.
    Schmidt C
    J Natl Cancer Inst; 2008 Mar; 100(6):382-3, 386. PubMed ID: 18334700
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA is coming! The FDA is coming!
    Leonard DG
    Mol Diagn; 2001 Sep; 6(3):153-4. PubMed ID: 11571707
    [No Abstract]   [Full Text] [Related]  

  • 8. New Food and Drug Administration-based oversight over genetic testing.
    Press RD
    Mol Diagn; 2001 Dec; 6(4):348-9. PubMed ID: 11837221
    [No Abstract]   [Full Text] [Related]  

  • 9. In search of a coherent framework: options for FDA oversight of genetic tests.
    Javitt GH
    Food Drug Law J; 2007; 62(4):617-52. PubMed ID: 18557224
    [No Abstract]   [Full Text] [Related]  

  • 10. Standard issue.
    Nature; 2010 Aug; 466(7308):797. PubMed ID: 20703263
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA user fees and innovation.
    Somberg J
    Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
    [No Abstract]   [Full Text] [Related]  

  • 12. Ready or not.
    Nature; 2008 Apr; 452(7188):666. PubMed ID: 18401360
    [No Abstract]   [Full Text] [Related]  

  • 13. Crunch time for multiple-gene tests.
    Gewin V
    Nature; 2007 Jan; 445(7126):354-5. PubMed ID: 17251949
    [No Abstract]   [Full Text] [Related]  

  • 14. Unapproved tests on a chip.
    Nature; 2005 Dec; 438(7069):711. PubMed ID: 16340967
    [No Abstract]   [Full Text] [Related]  

  • 15. An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...
    O'Kane D
    Clin Pharmacol Ther; 2010 Dec; 88(6):746-8. PubMed ID: 21081942
    [No Abstract]   [Full Text] [Related]  

  • 16. All together now.
    Nat Genet; 2001 Jan; 27(1):13. PubMed ID: 11191459
    [No Abstract]   [Full Text] [Related]  

  • 17. Food and drug administration expanded access to treatment: implications for oncology patients.
    Freedman RS; Markman M
    Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587
    [No Abstract]   [Full Text] [Related]  

  • 18. What's brewing in genetic testing.
    Nat Genet; 2002 Dec; 32(4):553-4. PubMed ID: 12457183
    [No Abstract]   [Full Text] [Related]  

  • 19. Discussion: The FDA is Unprepared for Personalized Medicine.
    Tabarrok A
    Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317
    [No Abstract]   [Full Text] [Related]  

  • 20. A warning that must not be ignored.
    Hudson K
    New Sci; 2003 May; 178(2393):5. PubMed ID: 14686409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.